Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Relationship Between Bone Density And Erosion In Arthritis
Rheumatoid arthritis (RA), the most common form of inflammatory arthritis, affects almost three percent of people over age 65. RA patients experience pain, functional limitations and two forms of disabling bone disease: focal erosions and osteoporosis. After five years of disease, up to 50 percent of RA patients show evidence of focal erosions and RA doubles the risk of osteoporosis and fractures. A new study examined the relationship between these two RA-related processes, in the hopes of providing insight into the underlying pathophysiology of RA-related bone disease. The study was published in the June issue of Arthritis & Rheumatism.

Pitt Study Redefines Binge Drinking For Children And Adolescents
The criteria used to assess blood alcohol concentrations (BACs) and binge drinking behaviors in children and adolescents should be based on pediatric rather than adult physiology, according to a new University of Pittsburgh study in the June issue of Pediatrics.
News of the day
New Cervical Cancer Campaign, UK
There will be a new drive to ensure GPs spot cervical cancer symptoms earlier in young women and refer patients correctly, Health Minister Ann Keen announced today.
Public Health

New Drug Combination Offers Novel Treatment Strategy For Non-Hodgkin's Lymphoma

Patients diagnosed with non-Hodgkin"s lymphoma who become resistant to standard therapies may have a new treatment option. Scientists in the Lymphoma Translational Research Laboratory at Roswell Park Cancer Institute analyzed the mechanisms to overcome treatment resistance, including a new drug combination. Francisco J. Hernandez-Ilizaliturri, MD , Departments of Medicine and Immunology, Roswell Park Cancer Institute (RPCI), will present the findings at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 - June 2, in Orlando, FL. "Strategies to Overcoming Rituximab-chemotherapy Resistance by Targeting the Autophagy Pathway Using Bortezomib in Combination with the Bcl-2 Inhibitor Obatoclax in non-Hodgkin"s Lymphomas (NHL)" Monday, June 1 - 5 pm EST Level 4, Valencia Room, W415A The Roswell Park investigators evaluated the biological effects of combining two drugs that target molecular pathways that play an important role in acquired resistance to standard therapies of rituximab and chemotherapy in non-Hodgkin"s lymphoma laboratory models. Obatoclax is an investigational drug designed to kill cancer cells by blocking a protein that usually prevents cell death. Bortezomib, the first approved cancer drug in a new class of medicines called proteasome inhibitors, disrupts the growth and survival of cancer cells. Scientists found that Obatoclax and Bortezomib are highly active against several lymphoma cell lines and tumor cells derived from patients with untreated or highly refractory lymphomas. When used in combination, the drugs demonstrated synergistic action. "This research contributes to the scientific understanding of the mechanisms responsible for rituximab resistance, which will ultimately result in the development of novel therapies and better outcomes for patients," said Dr. Hernandez-Ilizaliturri. "Our laboratory finding strongly suggests that Obatoclax and Bortezomib are an effective drug combination that has potential as a new treatment option for patients diagnosed with aggressive non-Hodgkin"s lymphoma and merits further investigation." The incidence of NHL has been steadily increasing over the past two decades and is now considered the second most rapidly increasing cause of cancer-related death in the United States. In 2009, approximately 65,980 new cases of NHL will be diagnosed and 19,500 patients will die from the disease. Roswell Park Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009